Eliksa Therapeutics, Inc.
Doylestown, PA
- UEI
- KXVVPMFRJC39
- CAGE
- 9XGL9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 3805 Old Easton Rd, Doylestown, PA 18902, USA
- Website
- eliksa.com
- Founded
- 2021
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Novel ophthalmic solution to treat ocular manifestations of epidermolysis bullosa | Defense Health Agency | $4,288,290 |
Quick answers
What is Eliksa Therapeutics, Inc.'s UEI?
Eliksa Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is KXVVPMFRJC39.
What is Eliksa Therapeutics, Inc.'s CAGE code?
Eliksa Therapeutics, Inc.'s CAGE code is 9XGL9.
What is Eliksa Therapeutics, Inc.'s primary NAICS code?
Eliksa Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Eliksa Therapeutics, Inc. located?
Eliksa Therapeutics, Inc.'s physical address in SAM.gov is 3805 Old Easton Rd, Doylestown, PA 18902, USA.
Is Eliksa Therapeutics, Inc. registered in SAM.gov?
Yes. Eliksa Therapeutics, Inc.'s SAM.gov registration is active through February 26, 2027.
What is Eliksa Therapeutics, Inc.'s most recent federal award?
Eliksa Therapeutics, Inc.'s most recent federal grant award is Novel ophthalmic solution to treat ocular manifestations of epidermolysis bullosa (HT94252410733), from Defense Health Agency, on July 1, 2024.
On GovTribe
See Eliksa Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors